中文摘要：

目的：探讨子宫内膜腺癌组织中血管内皮生长因子（VEGF）表达与雌激素受体（ER）α及β、孕激素受体（PR）的表达及其与临床病理特征的关系。方法：采用免疫组化（SP）方法检测93例子宫内膜腺癌（内膜腺癌组）和31例正常子宫内膜（正常内膜组）VEGF、ERα、ERβ及PR的表达。结果：1内膜腺癌组VEGF阳性表达率（58.1%）明显高于正常内膜组（32.3%）,而ERα的阳性表达率（59.1%）明显低于正常内膜组（80.6%）,差异均有统计学意义（P〈0.05）。ERβ、PR的阳性表达率差异无统计学意义（P〉0.05）。2在子宫内膜腺癌组织中,VEGF的阳性表达在病理分期和有无淋巴结转移中比较,差异有统计学意义（P〈0.05）;ERα的阳性表达率在病理分期、组织学分级、肌层浸润深度中比较,差异有统计学意义（P〈0.05）;PR的阳性表达率在病理分期和组织学分级中比较,差异有统计学意义（P〈0.05）;ERβ的阳性表达率在临床病理特征中的比较,差异均无统计学意义（P〉0.05）。3VEGF与ERα的表达呈负相关（r=-0.273,P=0.046）。结论：VEGF及ERα的表达与子宫内膜腺癌的发生发展及预后有关,VEGF及ERα的检测可能有助于评估子宫内膜腺癌的生物学行为和预后。

英文摘要：

Objective： To explore the expression of vascular endothelial growth factor（ VEGF）,estrogen receptor alpha（ ERα） and beta（ ERβ）,progterone receptor（ PR）,and their clinical pathological features in endometrial adenocarcinoma. M ethods： Immunohistochemistry was used to detect the expressions of VEGF,ERα ERβ,PR in93 cases of endometrial adenocarcinoma and 31 cases of normal endometrium. Results： 1 The expressions of VEGF in endometrial adenocarcinoma（ 58. 1%） were significantly higher than those in normal endometrium（ 32. 3%）（ P〈0. 05）,and the expressions of ERα in endometrial adenocarcinoma（ 59. 1%） were significantly lower than those in normal endometrium（ 80. 6%）（ P〈0. 05）,but there was no significant difference on the expression of ERβ and PR between the two groups（ P〈0. 05）. 2The VEGF expression in endometrial adenocarcinoma was significantly associated with surgical stages and myometrial invasion（ P〈0. 05）. The ERα expression was found to be inversely associated with surgical stages,histological grade and myometrial invasion（ P〈0. 05）;the PR expression was also inversely related with clinical stages and histological grades,but not related with ERβ（ P〈0. 05）. 3 There was a negative correction between VEGF and ERα in endometrial carcinoma（ r =-0. 273,P = 0. 046）. Conclusions： Expressions of VEGF and ERα may be correlation with tumorigenicity and prognosis of endometrial adenocarcinoma. The detection for VEGF and ERα may be helpful for evaluating biological behaviors and prognosis of patients with endometrial adenocarcinoma.